Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Trials Année : 2021

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

E. Berikova
  • Fonction : Auteur
E. Chang
  • Fonction : Auteur
V. Cox
  • Fonction : Auteur
A. Khan
  • Fonction : Auteur
U. Khan
  • Fonction : Auteur
K. O'Brien
  • Fonction : Auteur
O. Okunbor
  • Fonction : Auteur
L. Oyewusi
  • Fonction : Auteur
P. P. J. Phillips
  • Fonction : Auteur
L. Pichon
M. Tamirat
  • Fonction : Auteur

Résumé

Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings. Methods endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations. Discussion The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide. Trial registration ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.
Fichier principal
Vignette du fichier
s13063-021-05491-3.pdf (872.26 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

hal-03368536 , version 1 (06-10-2021)

Licence

Paternité

Identifiants

Citer

L. Guglielmetti, E. Ardizzoni, M. Atger, Emmanuel Baudin, E. Berikova, et al.. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.. Trials, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩. ⟨hal-03368536⟩
40 Consultations
43 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More